Internal Medicine, Medical Oncology · Lutherville, MD
NPI
1760413652
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
10755 Falls Rd
Lutherville, MD, 21093
Phone (410) 583-2970
Groups this clinician bills Medicare through
Medicare paid, 2024
$11.6M
326,675 services
Medicare patients, 2024
558
Average age 75
Drug cost, 2024
$1.4M
862 prescriptions
Company payments, 2025
$20.86
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Sharfman was code J9299 (injection, nivolumab, 1 mg), 61,760 times for 29 patients. In total William Sharfman billed 326,675 services in 118 codes, and Medicare paid $11.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 61,760 | 29 | $22.35 | $1.4M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 45,540 | 21 | $39.36 | $1.8M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 39,600 | 28 | $44.69 | $1.8M |
| J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | Office | 24,480 | 23 | $122.81 | $3.0M |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 17,980 | 12 | $0.06 | $1,006 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 10,500 | 16 | $0.12 | $1,215 |
| J9228 Injection, ipilimumab, 1 mg | Office | 8,325 | 15 | $127.22 | $1.1M |
| J9171 Injection, docetaxel, 1 mg | Office | 4,824 | 14 | $0.67 | $3,239 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 3,040 | 43 | $0.07 | $223 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,998 | 33 | $0.09 | $179 |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 959 | 19 | $2.59 | $2,485 |
| 96413 Chemotherapy Administration | Office | 956 | 128 | $106.56 | $102K |
| 99214 Office E&M - Established | Office | 609 | 282 | $101.09 | $62K |
| 96375 Injection Administration | Office | 402 | 50 | $12.82 | $5,153 |
| 96401 Chemotherapy Administration | Office | 371 | 22 | $58.53 | $22K |
By year: 2022 $6.3M for 215,569 services; 2023 $10.4M for 295,242 services; 2024 $11.6M for 326,675 services.
Medicare prescription drug claims, 2024
In 2024, the drug William Sharfman prescribed most often to Medicare patients was Levothyroxine Sodium, with 126 prescriptions and refills. In total William Sharfman wrote 862 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 126 | 207 | 28 | $1,009 |
| Pantoprazole Sodium Generic | 95 | 131 | 24 | $869 |
| Prednisone Generic | 88 | 132 | 31 | $515 |
| Oxycodone Hcl Generic | 66 | 70 | Under 11 | $4,489 |
| Hydrocortisone Generic | 46 | 100 | 12 | $2,864 |
| Mektovi Binimetinib | 32 | 32 | Under 11 | $400K |
| Braftovi Encorafenib | 31 | 31 | Under 11 | $464K |
| Lorazepam Generic | 22 | 25 | 11 | $58.86 |
| Morphine Sulfate Er Morphine Sulfate | 21 | 21 | Under 11 | $1,130 |
| Tramadol Hcl Generic | 19 | 20 | Under 11 | $114 |
| Eliquis Apixaban | 16 | 35 | Under 11 | $19K |
| Dexamethasone Generic | 16 | 24 | Under 11 | $386 |
| Ketoconazole Generic | 12 | 12 | Under 11 | $5,231 |
| Pregabalin Generic | 12 | 12 | Under 11 | $116 |
| Alprazolam Generic | 11 | 11 | Under 11 | $114 |
Brand drugs: 174 claims; generic drugs: 688 claims; opioid claims: 131.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Sharfman $20.86 ($20.86 in general payments such as food, travel and fees) from 6 companies. The largest payer was Gilead Sciences, Inc. with $20.86.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 1 | $20.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.